NCT01613300 2021-05-26Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B PatientsGrupo Español de Linfomas y Transplante Autólogo de Médula ÓseaPhase 2 Completed33 enrolled